Coumarin

Coumarin

SCHEMBL531571

N.O=c1ccc2ccccc2o1

nearest known ligand 0.95

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 11/20 0.95
CA9 Q16790 11/20 0.95
CA1 P00915 7/20 0.95
CA3 P07451 7/20 0.95
CA4 P22748 7/20 0.95
CA7 P43166 7/20 0.95
CA14 Q9ULX7 7/20 0.95
CA5A P35218 6/20 0.95
CA6 P23280 6/20 0.95
CA5B Q9Y2D0 5/20 0.95
CA2 P00918 5/20 0.95
MCL1 Q07820 4/20 0.95
TDP1 Q9NUW8 3/20 0.95
LMNA P02545 3/20 0.95
SOST Q9BQB4 1/20 0.95
PGR P06401 2/20 0.55
ALDH1A1 P00352 5/20 0.52
HPGD P15428 5/20 0.52
HSD17B10 Q99714 4/20 0.52
KDM4E B2RXH2 3/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Coumarin SCHEMBL8144767 1.00 CA12 (0.95) CA12CA9CA1CA3CA4
Coumarin SCHEMBL28077221 0.98 CA12 (0.91) CA12CA9CA1CA3CA4
Coumarin SCHEMBL6252 0.98 CA12 (1.00) CA12CA9CA1CA3CA4
Coumarin SCHEMBL3441294 0.98 CA12 (1.00) CA12CA9CA1CA3CA4
Coumarin SCHEMBL29385611 0.98 CA12 (1.00) CA12CA9CA1CA3CA4
Coumarin SCHEMBL621751 0.98 CA12 (1.00) CA12CA9CA1CA3CA4
Coumarin SCHEMBL1038138 0.98 CA12 (1.00) CA12CA9CA1CA3CA4
Coumarin SCHEMBL28886137 0.98 CA12 (1.00) CA12CA9CA1CA3CA4
Coumarin SCHEMBL4958503 0.95 CA12 (0.95) CA12CA9CA1CA3CA4
Coumarin SCHEMBL22721260 0.95 CA12 (0.95) CA12CA9CA1CA3CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110105345-B Benzofuran substituted coumarin amine derivative and application thereof in pollution resistance 扬州工业职业技术学院 2020-07-17 CN claimed
EP-2486078-B1 A LATENT CURING AGENT AND EPOXY COMPOSITIONS CONTAINING THE SAME HENKEL AG & CO KGAA (DE) 2018-02-21 EP claimed
CN-104311543-B A kind of synthesis and application of the tri-arylamine group dye sensitizing agent containing cumarin 浙江工业大学 2017-07-07 CN claimed
WO-2017044043-A1 PROCESS FOR DIRECT AMIDATION OF AMINES VIA RH(I)-CATALYZED ADDITION OF BOROXINES AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2017-03-16 WO claimed
US-9334426-B2 Latent curing agent and epoxy compositions containing the same HENKEL AG & CO. KGAA (DE) 2016-05-10 US claimed
CN-104311543-A Synthesis and application of coumarin-containing triarylamine dye sensitizing agent UNIV ZHEJIANG TECHNOLOGY 2015-01-28 CN claimed
US-20140235738-A1 LATENT CURING AGENT AND EPOXY COMPOSITIONS CONTAINING THE SAME HENKEL AG & CO. KGAA (DE) 2014-08-21 US claimed
US-20120238653-A1 LATENT CURING AGENT AND EPOXY COMPOSITIONS CONTAINING THE SAME HENKEL AG & CO. KGAA (DE) 2012-09-20 US claimed
EP-2486078-A1 A LATENT CURING AGENT AND EPOXY COMPOSITIONS CONTAINING THE SAME Henkel AG & Co. KGaA (DE) 2012-08-15 EP claimed
WO-2011042062-A1 A LATENT CURING AGENT AND EPOXY COMPOSITIONS CONTAINING THE SAME HENKEL AG & CO. KGAA (DE) 2011-04-14 WO claimed
CN-121494817-A Coumarin nitrogen-containing heterocyclic derivative and application thereof in antidiabetic activity 山西医科大学 2026-02-10 CN disclosed
EP-4585267-A2 COUMARIN BASED HSP90 INHIBITORS WITH UREA AND ETHER SUBSTITUENTS The University of Kansas (US) 2025-07-16 EP disclosed
EP-3068778-B1 COUMARIN BASED HSP90 INHIBITORS WITH UREA AND ETHER SUBSTITUENTS UNIV KANSAS (US) 2025-02-19 EP disclosed
WO-2024123412-A1 FERROPTOSIS INDUCERS TO TREAT CANCER THE UNIVERSITY OF TOLEDO (US) 2024-06-13 WO disclosed
WO-2024055291-A1 METHOD FOR HIGH-THROUGHPUT SCREENING OF SIRTUIN MUTANT, SIRTUIN MUTANT, AND USE THEREOF 中国科学院深圳先进技术研究院 2024-03-21 WO disclosed
US-6342379-B1 Detection of transmembrane potentials by optical methods THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2002-01-29 US disclosed
WO-2001042211-A2 DETECTION OF TRANSMEMBRANE POTENTIALS BY OPTICAL METHODS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2001-06-14 WO disclosed
US-6054114-A DIAGNOSING THE DEGREE OF PROGRESSION OF ALZHEIMER'S DISEASE IN A MAMMAL, MONITORING THE RESPONSE TO A THERAPY IN A MAMMAL HAVING ALZHEIMER'S DISEASE, IDENTIFYING AN AGENT USEFUL FOR TREATING ALZHEIMER'S DISEASE MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2000-04-25 US disclosed
WO-1997041856-A9 ORGANOMETALLIC LIGANDS FOR THE LOCALIZATION AND QUANTIFICATION OF AMYLOID IN VIVO AND $i(IN VITRO) 1998-10-01 WO disclosed
WO-1997041856-A1 ORGANOMETALLIC LIGANDS FOR THE LOCALIZATION AND QUANTIFICATION OF AMYLOID IN VIVO AND $i(IN VITRO) MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1997-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120238653-A1 LATENT CURING AGENT AND EPOXY COMPOSITIONS CONTAINING THE SAME MCM7, CES2, EPHX2 CA12 2268/4885CA9 2233/4885CA1 1626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.